Oncolytic herpes simplex virus vectors for cancer virotherapy
about
sameAs
Oncolytic viral therapy for pancreatic cancer: current research and future directionsSafety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates.Presage of oncolytic virotherapy for oral cancer with herpes simplex virus.Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism.Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesotheliomaTreatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47deltaVirally-directed fluorescent imaging (VFI) can facilitate endoscopic staging.Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptorA novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.Cancer gene therapy.Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.Oncolytic virotherapy for pancreatic cancer.Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.Gene therapy in orthopaedic surgery: the current status.Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.Oncolytic viral therapies.Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.Gene therapy applications of viral vectors.Oncolytic measles viruses for cancer therapy.Replication-selective oncolytic viruses in the treatment of cancer.Gene therapy and virotherapy of gastric cancer: preclinical results and clinical developments.Oncolytic viruses in the treatment of bladder cancerTreatment of breast cancer stem cells with oncolytic herpes simplex virus.Herpes simplex virus 1 (HSV-1) for cancer treatment.Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumorsGene therapeutics: the future of brain tumor therapy?Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastasesOncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human seraCombinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Gene therapy in head and neck cancer: a review.Oncolytic herpes viruses, chemotherapeutics, and other cancer drugsOncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61Selective anticancer strategies via intervention of the death pathways relevant to cell transformation.
P2860
Q27011439-BFBFC537-FFFC-4A2C-B90D-735301FF4D9CQ28210728-7B717EC4-F793-4437-BC91-FFE642227C6BQ33603748-09380454-900E-4BDE-9559-4F248785DE37Q33813146-B880D013-6707-4A35-94E3-E4438252A72EQ33894449-02F881FC-3937-4AAE-8D62-34936FE18BB4Q33911962-4BD2296E-E376-41F7-A336-CFBA7284A2DDQ33995471-BE12CB03-5440-418C-81BC-7C3B2C4FEA63Q34073330-26BF7ABC-EB6D-4DF8-95E5-7E2DA3D35CC3Q34313234-18FB834E-FBD5-4949-A086-685BA5DEB358Q34411569-A5FEA5C7-D18F-4201-830A-432D87862E59Q34423157-541C2337-C677-4B27-80C1-53702244E109Q34536549-9003773F-D5EC-4160-BBD6-6F4764D8FF4CQ34600345-913D67F4-53B1-4FF4-A3AE-98F71BA7AA5EQ35023915-39F129AC-EC7D-4BCE-981D-61F5FB547A55Q35081097-E7673C92-B50E-4D9E-A96F-FCEDCBA5FD0DQ35110264-DF0A8B0F-E75E-4FFE-AF26-01ED2005620CQ35590996-8A280E50-4FEA-49B3-91AC-4C0A151B29FFQ35625500-2646BE7C-21D2-4473-B3ED-30FC4B2CAE4CQ35630146-4A6BA90E-5A70-4755-A64F-6DD11C2788E9Q35649214-5F7114F8-F483-4F28-A5D8-FB7AC8675968Q35842621-F90C2F78-B9A7-498D-914D-8A780E62B363Q35852258-7ACFF845-326A-4838-9453-0914A43E68FFQ35867997-25758FC7-66D2-4E2F-9C4F-E6CBC38740E8Q35904004-9FEC6165-451D-471E-950D-B8C210523EE6Q35907056-1B0EF391-CB0F-47C7-A441-5CD5C3093574Q35912403-AD8D370D-FECB-4C04-AB25-26DB9CCBF94AQ36090054-5CE489B9-CD42-4C02-8135-CFA134819872Q36147934-6206F6FE-9A1F-4442-BB45-88636F4DCC08Q36241046-796F5E02-1A11-4CEC-AAF1-8566C48194FFQ36444443-8EA8CCD3-B73D-4A3E-BCB7-1B71F1649A8EQ36512525-E1EA3272-7CD8-4D2D-815C-A7814D6ECCF9Q36532106-608880FB-20A9-4AF2-BF19-8F011C1C8B50Q36546412-B576799F-B043-4A9D-8EB4-80830A115FBEQ36664245-5458C7E6-DC7D-4BD5-BC96-0D1DFA110732Q36700993-A52B69E6-F199-4EB7-88C2-842E51BB557CQ36849213-46670078-86A0-4941-9AC0-80B8C6A37D4AQ37023446-B952E328-B83C-4E46-B07C-312AB231A666Q37031896-98BE0211-5FAF-4482-B54E-92EC09374C22Q37138130-5D8AB77C-275E-436F-A380-58D368C3C5D8Q37147752-B168A99B-747E-44D2-87E1-61BFF1BE8C95
P2860
Oncolytic herpes simplex virus vectors for cancer virotherapy
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Oncolytic herpes simplex virus vectors for cancer virotherapy
@ast
Oncolytic herpes simplex virus vectors for cancer virotherapy
@en
Oncolytic herpes simplex virus vectors for cancer virotherapy
@nl
type
label
Oncolytic herpes simplex virus vectors for cancer virotherapy
@ast
Oncolytic herpes simplex virus vectors for cancer virotherapy
@en
Oncolytic herpes simplex virus vectors for cancer virotherapy
@nl
prefLabel
Oncolytic herpes simplex virus vectors for cancer virotherapy
@ast
Oncolytic herpes simplex virus vectors for cancer virotherapy
@en
Oncolytic herpes simplex virus vectors for cancer virotherapy
@nl
P3181
P356
P1433
P1476
Oncolytic herpes simplex virus vectors for cancer virotherapy
@en
P2093
Susan Varghese
P2888
P304
P3181
P356
10.1038/SJ.CGT.7700537
P407
P577
2002-12-01T00:00:00Z